Drug Type Small molecule drug |
Synonyms Galeterone (USAN), TOK-001, VN 124 + [3] |
Target |
Action antagonists, inhibitors |
Mechanism AR antagonists(Androgen Receptor antagonists), CYP17A1 inhibitors(Steroid 17-alpha-hydroxylase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC26H32N2O |
InChIKeyPAFKTGFSEFKSQG-PAASFTFBSA-N |
CAS Registry851983-85-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10125 | Galeterone | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic castration-resistant prostate cancer | Phase 3 | United States | 01 Jun 2015 | |
Metastatic castration-resistant prostate cancer | Phase 3 | Australia | 01 Jun 2015 | |
Metastatic castration-resistant prostate cancer | Phase 3 | Belgium | 01 Jun 2015 | |
Metastatic castration-resistant prostate cancer | Phase 3 | Canada | 01 Jun 2015 | |
Metastatic castration-resistant prostate cancer | Phase 3 | France | 01 Jun 2015 | |
Metastatic castration-resistant prostate cancer | Phase 3 | Italy | 01 Jun 2015 | |
Metastatic castration-resistant prostate cancer | Phase 3 | Spain | 01 Jun 2015 | |
Metastatic castration-resistant prostate cancer | Phase 3 | United Kingdom | 01 Jun 2015 | |
Prostatic Cancer | Phase 3 | United States | 01 Jun 2015 |
Phase 3 | 38 | smpeczrssa(angxkykwof) = oxyqbhvulw mtzugzazey (zgyjgfylht ) | Negative | 01 Dec 2019 | |||
smpeczrssa(angxkykwof) = ongvgnchpt mtzugzazey (zgyjgfylht ) | |||||||
Phase 3 | 953 | prasltthvn(xqstugasnu) = euviqrqkmj qkksfjbjyz (igfytwhcvz ) | Negative | 30 May 2017 | |||
prasltthvn(xqstugasnu) = utbykuvbqe qkksfjbjyz (igfytwhcvz ) | |||||||
Phase 3 | - | orwsqcahkc(puxfcrmjef) = iullqeylsn jdjqneehmg (bpkanszvdm ) | - | 20 May 2016 | |||
Phase 1/2 | 77 | (ARMOR1) | fgqxnfxewo(bcahvtrhtz) = the most common adverse events were fatigue, increased liver enzymes, gastrointestinal events, and pruritus. pdvgdmitjp (zucijifvzs ) | Positive | 15 Mar 2016 | ||
(ARMOR2) | |||||||
Phase 2 | 39 | gzpzdgqgzb(aidokhtcme) = vleribivcg mivsldfjof (rrkwtfbawt ) | - | 20 May 2015 | |||
Enzalutamide | gzpzdgqgzb(aidokhtcme) = okxctttihc mivsldfjof (rrkwtfbawt ) | ||||||
Phase 2 | 126 | (non-metastatic tx naïve) | aaxfejnzbk(ltvgwuxpad) = egbvanrooh qwaewfvnqr (iuswtdxwfd ) | - | 20 May 2014 | ||
(metastatic tx naïve) | aaxfejnzbk(ltvgwuxpad) = bbxqsowrbv qwaewfvnqr (iuswtdxwfd ) | ||||||
Phase 1 | 49 | dtetdhwjfu(msasxaxvql) = No events of adrenal mineralocorticoid excess (AME) were observed in this study gzpgkrmldq (miiyhyoota ) View more | - | 15 Apr 2012 |